F. No. ND/IMP/20/000068
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
New Drugs Division

FDA Bhawan, Kotla Road
New Delhi
Dated: 20/06/2020

To,

M/s Hetero Labs Limited
7-2-A2, Sanath Nagar,
Hyderabad,
Telangana- 500018

Subject: Grant of permission to manufacture and marketing of Remdesivir for Injection 100mg/vial (Lyophilized powder for Injection for IV Infusion)- regarding

Reference: Your online application no. ND/CT21/FF/2020/19824.

Sir,

Please find enclosed herewith permission No. **MF-ND-107/2020 dated 20/06/2020** in Form CT-23 under Drugs & Cosmetics Act 1940 and New Drug and Clinical Trial Rules, 2019 there under granted based on evaluation in consultation with Subject Expert Committee (SEC) as part of accelerated approval process considering the emergency situation and unmet medical need in light of Covid 19 outbreak for restricted emergency use in the country.

Please acknowledge the receipt of the same.

Yours faithfully,

(Dr. V. G. Somani)
Drugs Controller General (India)

Copy to: -

1. The Drugs Control Administration, Vengalraonager, Hyderabad - 500 038.
2. The Deputy Drugs Controller (India), CDSCO Zonal Office, CDSCO Bhavan, S.R. Nagar, Hyderabad-500 038.

F. No. ND/IMP/20/000068
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(New Drugs Division)

Form CT-23

(See Rules 81, 82,83 & 84)

PERMISSION TO MANUFACTURE PHARMACEUTICAL FORMULATION OF A NEW DRUG FOR SALE OR FOR DISTRIBUTION

Number of the permission and date of issue **MF-ND- 107/2020** dated **20/06/2020**

1. The Central Licensing Authority hereby grant permission to **M/s Hetero Labs Limited, 7-2- A2, Sanath Nagar, Hyderabad, Telangana- 500018 Tel** : +91 40 23704923/24/25, Fax : 0091-40-23704035, 23813359, e-mail: contact@heterodrugs.**com** (Name and full postal address of authorized agent with contact details of the Organization) to manufacture for sale of pharmaceutical formulation manufactured by a manufacturer specified below.

2. Details of manufacturer and its manufacturing site under the license

Serial No.	Name and address of manufacturer (Full name and address with telephone and e-mail address of manufacturer	Name and address of manufacturer (Full name and address with telephone and e-mail address of manufacturing site
01	M/s Hetero Labs Limited 7-2-A2, Sanath Nagar, Hyderabad, Telangana- 500018 Tel : +91 40 23704923/24/25 Fax : 0091-40-23704035, 23813359 Email: contact@heterodrugs.com	M/s Hetero Labs limited, C/O Aspiro Pharma Limited, Sy. No.321, Biotech Park, Phase-III, Karkapatla, Mulugu Mandal, Medak District -502279, Telangana, India Tel : 040-23704925 , FAX: 04023096171 E-Mail: srinivas.d@aspiropharma.com

3. Details of Pharmaceutical formulation

Name of the New Drug to be manufactured:	**Remdesivir for Injection 100mg/vial**
Dosage Form:	**Lyophilized powder for Injection for IV Infusion**
Composition	**Each Lyophilised vial contains- Remdesivir 100mg**
Indication	**For treatment of suspected or laboratory confirmed corona virus disease 2019 (COVID-19) in adults and children hospitalised with severe disease.**

Shelf life with storage Condition	Initially 03 months with storage condition to store Remdesivir injection 100mg/20ml vials at refrigerated temperature (2°C to 8°C) until required for use.

4. This is subject to the conditions prescribed in Chapter X of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

V.G

Central licensing Authority
Stamp

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, ITO
New Delhi-110002

Place: New Delhi

Date: 20/6/2020

Condition of permission

1. The new drugs shall conform to the specifications approved by the Central Licensing Authority;
2. The labeling of the drugs shall conform to the requirements specified in the Drugs and Cosmetics rules, 1945;
3. The label on the immediate container of the drug as well as the packing in which the container is enclosed should contain the following warning:

   "WARNING: To be sold by retail on the prescription of specialist for use in hospital/ institutional set up only" and the warning shall be in box with red back ground.
4. As post marketing surveillance, the applicant shall submit Periodic Safety Update Reports as specified in the Fifth Schedule;
5. All reported serious unexpected adverse reactions related to drug shall be intimated to the Central Licensing Authority and regulatory action resulting from their review shall be complied with;
6. No claims except those mentioned above shall be made for the drug without prior approval of the Central Licensing Authority;
7. **Specimen of the carton, labels, package insert that will be adopted for marketing the drug in the county shall be got approved from the Central Licensing Authority before the drugs is marketed;**
8. **Updated stability study data shall be submitted at periodic interval .If long-term stability data submitted do not cover the proposed shelf-life of the product, the stability study shall be continued to firmly establish the shelf-life and the complete stability data shall be submitted.**
9. **Written informed consent from each patient/ or his representative prior to administration of the drug shall be obtained. Informed consent form to be used should contain in a language understandable to the patient/ or his representative the factual detail about the drug, its restricted emergency use approval, alternative therapy available etc. The copy of**

CDSCO CDSCO

the informed consent form should be submitted to CDSCO before launching the drug product for marketing.

10. The dose of the drug for adult and paediatric patients weighing more than 40kg should be a single dose of 200mg infused intravenously over 30 to 120 minutes on day 1 followed by once daily maintenance dose of 100mg, infused intravenously over 30 to 120 minutes for 4 days and the dose for paediatric patients with body weight between 3.5kg and less than 40kg should be single loading dose of 5mg/kg IV infused over 30-120 minutes on day 1 followed by 2.5mg/kg IV infused over 30-120 minutes once daily for 4 days. Extension of administration of drug beyond 5 days to 10 days is not recommended.

11. The package insert of the product should contain the following:-
    a) Use of drug in patient with renal Impairment: Use in patients with renal impairment are based on potential risk and potential benefit considerations. Patients with eGFR greater than or equal to 30 mL/min are reported to have received remdesivir for treatment of COVID-19 with no dose adjustment of remdesivir. All patients must have an eGFR determined before dosing. Remdesivir is not recommended in adult and pediatric patients (>28 days old) with eGFR less than 30 mL/min or in full-term neonates (≥7 days to ≤28 days old) with serum creatinine greater than or equal to 1 mg/dL unless the potential benefit outweighs the potential risk.
    b) Use of drug in patient with hepatic Impairment: It is not known if dosage adjustment is needed in patients with hepatic impairment and remdesivir should only be used in patients with hepatic impairment if the potential benefit outweighs the potential risk. Hepatic laboratory testing should be performed in all patients prior to starting remdesivir and daily while receiving remdesivir.

12. The Label of the product should mention "For use in hospital/ institutional set up only".
13. The Package Insert containing all details including the information as above and Informed Consent Form should be provided along with the drug product for use in hospital/ institutional.
14. Results of additional clinical trials as available should be submitted at the earliest atleast within 9 months.
15. Active surveillance data of all treated patients should be submitted to CDSCO on monthly basis.
16. The Risk Management Plan including active Post Marketing Surveillance (PMS) and reporting of Serious Adverse Events (SAEs) etc. should be submitted to CDSCO within one month of approval of the drug product.
17. Phase IV clinical trial is required to be conducted after getting the Phase IV clinical trial protocol approved from CDSCO.
18. As per records samples have been sent to CDTL, Mumbai and are under test which has been examined and it is directed that firm should submit test report from CDTL Mumbai before marketing.